AIM 7: THE PREVENTION OF NOCTURNAL HYPOGLYCEMIA IN TYPE 1 DIABETES

目标 7：预防 1 型糖尿病夜间低血糖

• 批准号: 7377210
• 负责人: PHILIP E. CRYER
• 金额: $ 4.46万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377210
• 关键词: AIM; PREVENTION; NOCTURNAL; HYPOGLYCEMIA; TYPE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Iatrogenic hypoglycemia, particularly nocturnal hypoglycemia, is the limiting factor in the glycemic management of diabetes (Cryer et al, Diabetes Care 26:1902, 2003). Using the nocturnal nadir plasma glucose concentration as the primary endpoint, we plan to contrast three bedtime treatments that have been reported to be effective - terbutaline, cornstarch, acarbose - with the standard treatment, a conventional bedtime snack, and no treatment in patients with type 1 diabetes who are managing their diabetes aggressively as evidenced by a HbA1c of <=8.0% and a goal of morning self-monitoring of blood glucose values <=120mg/dL. Patients will be sampled during five overnight GCRC stays with the bedtime treatments given in random sequence.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。医源性低血糖，特别是夜间低血糖，是糖尿病血糖控制的限制因素（Cryer等人，Diabetes Care 26：1902，2003）。使用夜间最低血糖浓度作为主要终点，我们计划将三种已报告有效的睡前治疗方法--特布他林、玉米淀粉、阿卡波糖--与标准治疗（传统的睡前零食）进行比较，在积极管理糖尿病的1型糖尿病患者中未接受治疗，如HbA 1c <=8.0%和早晨自我管理目标所证明。监测血糖值<= 120 mg/dL。将在5次过夜GCRC停留期间对患者进行采样，并按随机顺序进行睡前治疗。